CA 19-9: Biochemical and Clinical Aspects
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis a antigen) is the most commonly used and best validated serum tumor marker for pancreatic cancer diagnosis in symptomatic patients and for monitoring therapy in patients with pancreatic adenocarcinoma. Normally synthesized by normal human pancreatic and biliary ductal cells and by gastric, colon, endometrial and salivary epithelia, CA 19-9 is present in small amounts in serum, and can be over expressed in several benign gastrointestinal disorders. Importantly, it exhibits a dramatic increase in its plasmatic levels during neoplastic disease. However, several critical aspects for its clinical use, such as false negative results in subjects with Lewis (a-b-) genotype and false positive elevation, occasional and transient, in patients with benign diseases, together with its poor positive predictive value (72.3 %), do not make it a good cancer-specific marker and renders it impotent as a screening tool. In the last years a large number of putative biomarkers for pancreatic cancer have been proposed, most of which is lacking of large scale validation. In addition, none of these has showed to possess the requisite sensitivity/specificity to be introduced in clinical use. Therefore, although with important limitations we well-know, CA 19-9 continues being the only pancreatic cancer marker actually in clinical use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell Genetics · doi:10.1007/bf01542654 · Cited by 1,364
Expression profiling identifies microRNA signature in pancreatic cancer
Lee, E. J., Gusev, Y., Jiang, J., Nuovo, G. J., Lerner, M. R., Frankel, W. L., Morgan, D. L., Postier, R. G., Brackett, D. J., & Schmittgen, T. D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22394 · Cited by 896
Goonetilleke, K. S., & Siriwardena, A. K. (2007) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2006.10.004 · Cited by 877
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784
Ballehaninna, U. K., & Chamberlain, R. S. (2012) · PubMed · doi:10.3978/j.issn.2078-6891.2011.021 · Cited by 701
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals
Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.005 · Cited by 648
Research works printed but not linked: 4
- Hakomori S, Kannagi R (1983) Glycosphyngolipids as tumor-associated and differentiation markers. J Natl Cancer Inst (Bethesda) 71:231–251
- Frebourg T, Bercoff E, Manchon N et al (1988) The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 62:2287–2290 · doi:10.1002/1097-0142(19881201)62:11<2287::aid-cncr2820621103>3.0.co;2-h
- National Health Insurance Corporation (2000) National health insurance statistical yearbook 1999, 21:350–563
- Sturgeon C, Dati F, Duffy MJ et al (1999) Quality requirements and control: EGTM recommendations. Anticancer Res 19:2785–2820
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“The subset of cancer-derived molecules (e.g., CA125, Sialyl-Tn and CA19-9) that survive such clearance then become useful markers of disease progression (948) (949) (950) (951) .”
BackgroundPancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 865
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
Lee, T., Teng, T. Z. J., & Shelat, V. G. (2020) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v12.i12.468 · Cited by 293
Metadata
- Authors
- Scarà, S., Bottoni, P., & Scatena, R.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Bottoni, Patrizia
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer Netherlands
- Published
- 2015
- Volume
- 867
- Pages
- 247-260
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W2184169423
- Cited by
- 351
- References
- 83
- Citations by year
- 2026: 33 · 2025: 46 · 2024: 51 · 2023: 40 · 2022: 48 · 2021: 39 · 2020: 29 · 2019: 26 · 2018: 21 · 2017: 11 · 2016: 6
- FWCI
- 25.12
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- CA19-9, pancreatic cancer, serum tumor markers, pancreatic ductal adenocarcinoma, cancer screening, false-negative results, benign gastrointestinal disease, biomarkers, treatment monitoring
- MeSH terms
- Humans, Pancreatic Neoplasms, Sensitivity and Specificity, CA-19-9 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CA 19-9: Biochemical and Clinical Aspects. https://app.cochat.ai/papers/10.1007/978-94-017-7215-0_15
- The paper
- Scarà, S., Bottoni, P., & Scatena, R. (2015). CA 19-9: Biochemical and Clinical Aspects. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-94-017-7215-0_15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.